Tralokinumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tralokinumab. Educational only — not medical advice.
Labeled uses
ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.
Source: FDA labeling via NIH DailyMed (set d8020b69…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.